Friday, February 18, 2005
Vioxx back on the shelf?
Ohhh, this will be something to keep an eye on.
If the FDA approves this, expect Merck stock to go through the roof as all those class action law suits are crushed.
Update: It's a go.
- An advisory panel is set to decide whether to recommend future sales of arthritis drugs Vioxx, Celebrex and Bextra despite data linking the drugs to higher risks of heart attacks.
Merck & Co. Inc. made a surprise announcement Thursday that it would consider selling Vioxx again if the Food and Drug Administration decided the cardiovascular risks were similar to those of related prescription pain relievers.
If the FDA approves this, expect Merck stock to go through the roof as all those class action law suits are crushed.
Update: It's a go.
![[ Registered ]](http://www.diarist.net/support/banners/dnbutt14.gif){kind=small}
![[ Registered ]](http://www.ehsany.com/blogshares5.gif){kind=small}
![[ Registered ]](http://feedster.net/i/addtomyfeedster4.gif)
